A healthy investment in healthier futures.

Cryo-Cell has been a publicly traded company since 1991. Governed by the Securities & Exchange Commission, our common stock trades under the OTC QB: symbol CCEL. We specialize in stem cell preservation for family use.

Cryo-Cell Reports Second Quarter 2013 Results

OLDSMAR, Fla. – July 15, 2013 Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL), the world’s first private cord blood bank to separate and store stem cells in 1992, today announced results for the second quarter ended May 31, 2013. 
 
“I am pleased to report Cryo-Cell’s second quarter results for fiscal year 2013, and in particular, cash flow from operations of almost $600,000, which we believe indicates that Cryo-Cell is growing stronger day by day,” stated David Portnoy, Cryo-Cell’s Chairman and Co-CEO.  “Key metrics of performance such as the 10% increase in revenues, during the second quarter of fiscal 2013 as compared to the second quarter of fiscal 2012 are encouraging.”  Mr. Portnoy continued, “Nonrecurring expenses in the quarter relating to legacy issues included 1.) an additional accrual relating to severance payment to a former executive of $219,000, and 2.) the write-off of approximately $379,000 related to the abandonment of certain previously incurred patent expenses.”
 
Mark Portnoy, Cryo-Cell’s Co-CEO, added, “We are pleased to see the continued improvement in our business results.  The earnings from business operations in the first half of the year demonstrate that our new sales and marketing initiatives have gained traction.”

Read More


Cryo-Cell Reports First Quarter 2013 Results

OLDSMAR, Fla. – April 5, 2013 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, today announced results for the first quarter ended February 28, 2013.  
 
“I am pleased to report Cryo-Cell’s first quarter results, and in particular, cash flow from operations of slightly more than $500,000, which we believe indicates that the Cryo-Cell turnaround is well underway,” stated David Portnoy, Cryo-Cell’s Chairman and Co-CEO.  “Key metrics of performance such as the increase in revenues and the number of specimens processed of 10% and 12%, respectively, during the first quarter of fiscal 2013 as compared to the first quarter of fiscal 2012 are encouraging.”
 
Mark Portnoy, Cryo-Cell’s Co-CEO, added, “It is gratifying to see the progress the Company has made over the last year although we are still dealing with a variety of legacy issues.  With the continued execution of the new sales and marketing initiatives, I expect to see further increases in revenue and earnings.”

 

Read More


Cryo-Cell Reports Financial Results and Results of Recent Shareholder Vote

Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL), today announced financial results for the second quarter ended May 31, 2012, and the results from the July 10, 2012, Annual Meeting of Shareholders.

 

 

Read More


Key Stakeholders Support Cryo-Cell International Leadership in Proxy Contest

Individuals who are in the best position to observe and evaluate the performance of the current Cryo-Cell International [OTCQB Symbol: CCEL] Board and executive management are strongly supporting them as they face a bid for control of the company by a former Board member. The group assumed leadership in August 2011.

 

 

Read More


Cryo-Cell Leadership Sets the Record Straight on Efforts to Date

Cryo-Cell International, Inc. [OTCQB Symbol: CCEL] updated shareholders with results achieved by the current Board's leadership, which is being challenged for control of the company by previous Board members Ki Yong Choi and his brother-in-law.

 

 

Read More


|<<1 2 3 4 5 6>>|